|
|
|
|
|
|
| |
| |
|
|
|
| |
|
| |
|
|
|
| |
 |
Gene expression arrays
Agilent whole human genome oligonucleotide arrays were used
for any transcriptomic analysis carried out at IOB. A 60-mer
oligonucleotide probe represents each spot in an array. Each
array contains 44k spots representing 41,000 genes. A high
density array, 4X44K was used for simultaneous analysis of
4 samples.
|
|
| |
|
|
|
| |
 |
Array CGH
High resolution whole human genome array from Agilent was
used to analyze copy number variations. High throughput analyses
were carried out using high density arrays 4X44K or 8X60K, where 4 or 8 samples could be analyzed simultaneously.
Comprehensive probe coverage spans coding and non-coding regions
with emphasis on known genes, promoters, miRNAs, disease, pseudoautosomal,
and telomeric regions.
|
|
| |
|
|
|
| |
 |
Custom designed human X-chromosome tiling arrays
IOB has designed human X-chromosome tiling microarrays using
Agilent’s e-array, a web portal for designing custom
arrays. The custom designed array has 244,000 probes
covering human X-chromosome with an average spacing of 635
bp that provides high resolution. The array encompasses
unique probes that represent most exons of the X-chromosome
genes. These arrays will be able to detect micro-duplications
and micro-deletions of size less than 1 Kb. These custom
designed high resolution X-chromosome tiling arrays will be
used to study the copy number variations in X-linked mental
retardation.
|
|
|
|
| |
 |
Tissue microarrays and Cell pellet arrays
Use of tissue microarrays and cell pellet arrays provides
us another high throughput platform to validate and test numerous
potential biomarkers which have been identified using high
resolution genomic and proteomic technologies. Advantage
of using these microarrays is that we can validate a potential
molecular signature in cancer or any other context against
hundreds of tissue samples or cell lines belonging to different
pTNM, age group, gender and population. This will also
provide confidence and statistical proof for the biomarkers
identified from otherwise low number of samples used for DNA
microarrays and mass spectrometry approaches in the biomarker
discovery phase.
|
|
|
|
|
|
| |
|
|
|
|
| |
|